Milan-based private oncology research hospital specializing in chromatin biology, cancer genomics, and translational epigenetics across 25 EU projects.
IEO is a private oncology research hospital in Milan that combines clinical cancer care with deep molecular biology research. Their work spans cancer genomics, chromatin biology, stem cell research, and translational oncology — bridging laboratory discoveries with patient-facing diagnostics and treatment. They contribute specialized expertise in epigenetics, gene regulation, and preclinical cancer models to large European consortia, and operate as a key node in cancer research infrastructure including patient-derived xenograft biobanks and proteomics access platforms.
Central theme across MEDICI (coordinated, €1.4M), DissectPcG, Chromatin3D, ChromDesign, and ENHPATHY — covering transcription factors, histone modifications, Polycomb complexes, and enhancer function.
Spans clinical and preclinical work including iManageCancer, FORECEE (cervical cancer prediction), BOUNCE (breast cancer adaptation), CARDIOCARE (cancer cardiotoxicity), OPTIMA (AI-guided treatment), EDIReX (xenograft infrastructure), and oncNGS (NGS diagnostics).
EuroStemCell (stem cell communication), DissectPcG (intestinal stem cells and cancer), and DUPDOWN (iPSC-derived brain organoids for autism research).
Increasingly prominent in recent projects: oncNGS (liquid biopsies, NGS), EPIC-XS (proteomics infrastructure), ChromDesign (3D genomics), and ENHPATHY (reporter assays, genome topology).
EDIReX provides trans-national access to patient-derived xenograft biobanks; ITHACA (coordinated) developed phage display targeting of quiescent leukemia cells.
Recent projects OPTIMA (AI for solid tumour treatment), CARDIOCARE (interdisciplinary patient management), and SMARTsurg (robotic surgery) signal growing digital health involvement.
In the early H2020 period (2015–2018), IEO focused on fundamental chromatin biology, endocrine disruptors, stem cell communication, and gender equality in research — a broad portfolio mixing basic science with societal themes. From 2019 onward, their work sharpened toward applied genomics, cancer infrastructure (xenograft biobanks, proteomics platforms), and data-driven oncology including AI-assisted treatment and NGS diagnostics. The trajectory shows a clear shift from fundamental epigenetic research toward translational and infrastructure-oriented cancer genomics.
IEO is moving from fundamental epigenetic research toward applied cancer genomics, digital oncology tools, and shared research infrastructure — expect future projects combining omics data with clinical decision support.
IEO overwhelmingly participates as a partner (20 of 25 projects) rather than leading consortia, with only 2 coordinator roles (MEDICI and ITHACA). They consistently join large, multi-country consortia — their 289 unique partners across 30 countries demonstrate a highly networked but non-dominant collaboration pattern. This makes them a reliable specialist contributor who brings deep oncology and epigenetics expertise without competing for consortium leadership.
IEO has collaborated with 289 unique partners across 30 countries, making them one of the more broadly connected cancer research organizations in H2020. Their network spans all major European research nations with no narrow geographic bias, reflecting their position in pan-European health and genomics consortia.
IEO occupies a rare position as a private research hospital that operates at the intersection of fundamental chromatin/epigenetic science and clinical oncology — most organizations do one or the other. Their dual capacity to contribute molecular biology expertise (Polycomb, transcription, histone modifications) alongside clinical cancer infrastructure (xenograft biobanks, patient cohorts, NGS diagnostics) makes them a uniquely versatile partner. For consortium builders, IEO offers a single partner that can bridge the gap between bench-level epigenomics and bedside cancer care.
